Details of the Drug Reposition

General Information of This Drug (ID: DM4O2Z7)

Drug Name
Cyclophosphamide   DM4O2Z7
Synonyms
ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
10 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Central nervous system neoplasm DISFC18W N.A. Approved [1]
Glioblastoma DISI0V5E 2A00 Approved [1]
Advanced cancer DISAT1Z9 2A00-2F9Z Approved [1]
Lymphoma DISN6V4S 2A80-2A86 Approved [1]
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [1]
Mycosis fungoides DIS62RB8 2B01 Approved [1]
Inflammatory breast cancer DIS3QRWA 2C62 Approved [1]
Immunodeficiency DIS093I0 4A00-4A85 Approved [1]
Lupus nephritis DISCVGPZ 4A40.0Y Approved [1]
Multiple sclerosis DISB2WZI 8A40 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Indications(s)
4 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia DISNAKFL N.A. Discontinued in Phase 2 [2]
Post-transplant lymphoproliferative disorder DISTS43D 2B32 Discontinued in Phase 2 [3]
Ewing sarcoma DISQYLV3 2B52 Discontinued in Phase 2 [4]
Metastatic melanoma DISSL43L 2E2Z Discontinued in Phase 2 [5]
------------------------------------------------------------------------------------
4 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Classic Hodgkin lymphoma DISV1LU6 N.A. Investigative [1]
Retinoblastoma DISVPNPB 2D02.2 Investigative [1]
Neuroblastoma DISVZBI4 2D11.2 Investigative [1]
Scleroderma DISVQ342 4A42 Investigative [1]
------------------------------------------------------------------------------------

References

1 Cyclophosphamide FDA Label
2 Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
3 Ketamine in Chronic Kid's (KiCK) Pain
4 The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis
5 A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma